HOME >> BIOLOGY >> NEWS
Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences

Many diseases (including inherited disorders like cystic fibrosis to cancer) have a genetic component and gene therapy holds the promise of restoring compromised genes with their healthy counterparts. That promise was quashed when a teenager -- Jesse Gelsinger -- suffering from a rare hereditary liver disorder died after participating in an experimental gene therapy trial in 1999. In another case, two young boys who received gene therapy for the severe immunodeficiency disorder known as "bubble boy disease" developed leukemia-like symptoms 30 months after treatment. In this case, the viral vector inserted itself near a promoter region -- a site that initiates gene transcription -- of a proto-oncogene, a gene that can initiate cancer. Since viral vectors can integrate at various genomic locations, the safety and effectiveness of gene therapy ultimately depends on being able to predict a virus's particular bias.

In order to determine whether different viruses have greater gene therapy potential, Rick Mitchell et al. compared retroviral vectors derived from three viruses and report 3,127 sites where these viruses typically integrate into the human genome. The different vectors, they found, show different target preferences. Mitchell et al. studied vectors derived from the human immunodeficiency virus (HIV), avian sarcoma-leukosis virus (ASLV), and murine leukemia virus (MLV). Introducing the viral vectors into human cells, the authors analyzed the gene expression profiles of the cells to determine where vectors integrate into human chromosomes and which, if any, genes they activate. Each retrovirus, they discovered, showed distinct preferences for genome integration. HIV vectors tend to integrate into sites of active transcription, favoring chromosomal regions rich in expressed genes. MLV vectors tend to integrate near transcription initiation sites, confirming the results of a previous study, with a weak bias toward active genes. In contrast, the authors rep
'"/>

Contact: Paul Ocampo
pocampo@plos.org
1-415-624-1224
Public Library of Science
16-Aug-2004


Page: 1 2

Related biology news :

1. Retroviral protein triggers proliferation of immune cells
2. An alternative form of chemotherapy? A means for reusable spacecraft?
3. Researchers identify distinctive signature for metastatic prostate cancer
4. DNA tests point to extinction of 2 distinctive arctic bird populations
5. Members receive distinction as fellows of agronomy society
6. Members receive distinction as fellows of crops society
7. Researchers identify protein modules that read distinct gene silencing codes
8. UCLA neuroscientists discovery distinct molecular key to overcoming fear
9. Gene tug-of-war leads to distinct species
10. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
11. Safety of isoflavones in dietary supplements targeted by Illinois initiative

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2019)... ... August 19, 2019 , ... Since ... use of ultra-thin two dimensional slices which are placed on microscope slides, stained ... complex tissues and complicated features such as vasculature and thus researchers in the ...
(Date:8/15/2019)... ... ... Deep Science Ventures (DSV), a new paradigm for applied science, today announced ... 100 companies over the next 10 years to address the urgent need for new ... was founded to create a better method for launching science companies; one that takes ...
(Date:8/15/2019)... ... , ... Serialization deadlines in the US and European Union ... becomes fully applied in the United States in 2023, pharmaceutical companies are scrutinizing ... most regulations?including the Drug Supply Chain Security Act (DSCSA)?have required minimal system capabilities. ...
Breaking Biology News(10 mins):
(Date:7/9/2019)... ... July 08, 2019 , ... Today, at the BIO World Congress ... Association (NCGA) announced the winners of the Consider Corn Challenge II. Three winners ... field corn to produce biobased materials. , “Corn is a sustainable, abundant and ...
(Date:6/18/2019)... ... ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell ... of a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical ... IND is the first of several planned clinical trials which will enable qualified PSC-enrolled ...
(Date:6/11/2019)... and ROANOKE, Va. (PRWEB) , ... June 11, ... ... optimized for microlearning engagement, and Carilion Clinic, a national leader in opioid treatment, ... latest in virtual care. , Mytonomy recently deployed its virtual care ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... providing proprietary interest to our methodology, processes, and diagnostic techniques. The patent ... extends Somnology’s IP rights including our proprietary sleep scoring methodology. The approval ...
Breaking Biology Technology:
Cached News: